tirzepatide week 4 weight loss percentage weight-loss study shows promising results Tirzepatide and Injectable Semaglutide Correlated

Your prescriber will advise on the exact needle length for your preferred injection site

18.2% average weight loss at week 68 was observed in patients in the STEP 4 trial, along with reduced blood glucose levels, improved lipid profile and significant improvements in overall quality of life and health status scores

Significant weight loss typically begins within the first month as we titrate your dose to the therapeutic level

If the medication freezes, the proteins will be destroyed

Significant weight regain during the switch is unlikely because the overlapping pharmacokinetics of both medications prevent a complete gap in appetite suppression